Atossa Therapeutics, Inc.
ATOS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001488039
No open-market purchases or sales by Atossa Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $2.60M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Atossa Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Atossa Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Steinhart Richard I | Director | 10,000 | May 14, 2026 | 1 |
| Remmel H. Lawrence | Director | 10,683 | May 14, 2026 | 1 |
| Galli Stephen J | Director | 10,006 | May 14, 2026 | 1 |
| Chen Shu-Chih | Director | 10,000 | May 14, 2026 | 1 |
| Finn Jonathan | Director | 11,666 | May 14, 2026 | 1 |
| Cigler Tessa | Director | 10,000 | May 14, 2026 | 1 |
| Quay Steven C | President & CEO | 88,038 | Mar 31, 2026 | 2 |
| Daniel Mark James | Chief Financial Officer | 63,000 | Mar 30, 2026 | 2 |
| Rees Heather | Chief Financial Officer | – | May 16, 2025 | 0 |
| Weaver Gregory L | Former EVP, CFO, & Director | 55 | Nov 17, 2023 | 0 |
| Guse Kyle | CFO, Gen Counsel and Secretary | – | Mar 6, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 22, 2025 (view filing) | May 21 | 1 day | Quay Steven CPresident & CEO | PPurchase | +11.2K | $0.88 | +$9.89K | +422.7%13.9K after | |
| Mar 28, 2025 (view filing) | Mar 26 | 2 days | Remmel H. LawrenceDirector | PPurchase | +10.0K | $0.70 | +$7.00K | +3,891.1%10.3K after | |
| Apr 11, 2024 (view filing) | Apr 10 | 1 day | Finn JonathanDirector | PPurchase | +25.0K | $1.77 | +$44.3K | New position25.0K after | |
| Nov 17, 2023 (view filing) | Nov 15 | 2 days | Weaver Gregory LFormer EVP, CFO, & Director | SSale | −50.0K | $0.65 | −$32.5K | −99.9%55 after | |
| Jun 20, 2023 (view filing) | Jun 20 | Same day | Weaver Gregory LEVP & CFO | PPurchase | +50.0K | $0.97 | +$48.5K | +90,909.1%50.1K after | |
| Jul 7, 2021 (view filing) | Jul 2 | 5 days | Weaver Gregory LDirector | SSale | −107.5K | $5.58 | −$599.8K | −100.0%0 after |